VIKING THERAPEUTICS INC (VKTX) Stock Price, Quote, News and Overview
NASDAQ:VKTX - Nasdaq - US92686J1060 - Common Stock - Currency: USD
VKTX Quote, Performance and Key Statistics
VIKING THERAPEUTICS INC
NASDAQ:VKTX (1/24/2025, 5:12:30 PM)
After market: 34.6501 +0.15 (+0.44%)34.5
-0.44 (-1.26%)
The current stock price of VKTX is 34.5 USD. In the past month the price decreased by -18.48%. In the past year, price increased by 61.44%.
VKTX Latest News, Press Releases and Analysis
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks.
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks
Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover.
VKTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About VKTX
Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2015-04-29. The firm's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The firm is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The company is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
Company Info
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA 92130 US
CEO: Brian Lian
Employees: 33
Company Website: https://vikingtherapeutics.com/
Investor Relations: http://ir.vikingtherapeutics.com/
Phone: 18587044660
VKTX FAQ
What is the stock price of VKTX?
The current stock price of VKTX is 34.5 USD.
What is the symbol for VIKING THERAPEUTICS INC stock?
The exchange symbol of VIKING THERAPEUTICS INC is VKTX and it is listed on the Nasdaq exchange.
On which exchange is VKTX stock listed?
VKTX stock is listed on the Nasdaq exchange.
Is VKTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VKTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VKTX.
Does VKTX stock pay dividends?
VKTX does not pay a dividend.
When does VKTX stock report earnings?
VKTX will report earnings on 2025-02-05, after the market close.
What is the Price/Earnings (PE) ratio of VKTX?
VKTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).
What is the Short Interest ratio of VKTX stock?
The outstanding short interest for VKTX is 18.88% of its float.
VKTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VKTX. When comparing the yearly performance of all stocks, VKTX turns out to be only a medium performer in the overall market: it outperformed 50.89% of all stocks.
VKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VKTX. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability.
VKTX Financial Highlights
Over the last trailing twelve months VKTX reported a non-GAAP Earnings per Share(EPS) of -0.93.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.57% | ||
| ROE | -10.88% | ||
| Debt/Equity | 0 |
VKTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to VKTX. The Buy consensus is the average rating of analysts ratings from 21 analysts.